Hansa Biopharma Appoints Two New Board Members
Hansa Biopharma AB (publ) has appointed Shannon Campbell and Gregory Perry to its Board of Directors. The new members were elected effective September 22, 2026.
Lund, Sweden-based Hansa Biopharma AB (publ) has added two new members to its Board of Directors. Shannon Campbell and Gregory Perry were elected to the board, with their terms effective September 22, 2026, and extending until the end of the next Annual General Meeting.
The company, which focuses on treatments for rare diseases, stated that the appointments are intended to support its strategic objectives. Campbell brings commercial and product launch experience, primarily from the U.S. market.
Gregory Perry's expertise lies in finance, governance, and strategic transactions aimed at creating value. Peter Nicklin, Chairman of the Board, commented that both appointees bring valuable additional expertise that will support Hansa Biopharma's ongoing development.
Hansa Biopharma is listed on Nasdaq Stockholm under the ticker HNSA. The company is dedicated to developing and commercializing enzyme replacement therapies for patients suffering from rare and life-threatening conditions.